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Summary
Design: The influence of demographic factors upon antimicrobial resistance among
3362 isolates of Streptococcus pneumoniae from 25 countries was investigated, using
univariate comparison and multivariate logistic regression.
Results: Eleven countries had significantly higher rates (Odds ratios [OR]: 2.50—
64.79) of penicillin and/or erythromycin resistance than the UK. After taking country
effects into account, rates of penicillin resistance (OR 1.98) and erythromycin
resistance (OR 1.89) were significantly higher among infants than adults. Fewer
(OR 0.69) erythromycin-resistant isolates were collected from male than female
patients. There was no difference in the incidence of penicillin or erythromycin
resistance among inpatients or outpatients. Penicillin resistance was more prevalent
among ear swabs than blood cultures (OR 2.07). Erm(B), the predominant macrolide
resistance mechanism across all age groups, was particularly prevalent among
bronchoalveolar lavage (69.1%) and sinus (68.8%) isolates. Isolates possessing both
erm(B) andmef(A) were generally collected from South Korea and weremost common
among infants and children (10.3%) and ear samples (17.3%). Telithromycin suscept-
ibility was >99.5%, irrespective of demography.
Conclusions: Althoughdemographyhada significant impactonantimicrobial resistance
of pneumococci, telithromycin remained highly active across all demographic groups.
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Over the last two decades, resistance to commonly
used antibacterial agents among Streptococcus
pneumoniae, the major bacterial pathogen impli-
cated in community-acquired respiratory tract
infections (RTIs), has spread at an alarming pace
around the globe.1,2 The clinical impact of this
resistance in the management of community-
acquired RTIs is becoming evident, with cases of
treatment failure in patients infected with a resis-
tant pneumococcal strain being reported with
increasing frequency in recent years.3—6 However,
the impact of drug-resistant S. pneumoniae, espe-
cially b—lactam resistance, is controversial as an
international prospective study of 844 hospitalized
patients failed to show a relationship between dis-
cordant therapy (i.e. inactive in vitro) and higher
mortality rate.7
International surveillance studies play an impor-
tant role in determining the extent of the resistance
problem, charting the movement of important resis-
tance phenotypes and genotypes across the globe,
and monitoring the progress of intervention strate-
gies designed to halt the progress of such strains.8,9
They can also help guide antibacterial selection and
assist in the development of antibiotic usage poli-
cies and guidelines by providing regional informa-
tion on the antibacterial susceptibilities of the key
community-acquired RTI pathogens, and the like-
lihood of a resistant strain being encountered in a
given patient. Although factors such as patient age,
site of infection, and isolate source have been
shown to influence the prevalence of resistance
among S. pneumoniae reported in surveillance stu-
dies,10—13 few large-scale studies have routinely
collected and analyzed data according to demo-
graphic parameters. Against this background, PRO-
TEKT (Prospective Resistant Organism Tracking and
Epidemiology for the Ketolide Telithromycin), an
international, longitudinal surveillance study, was
initiated in 1999 to monitor the susceptibility of
common respiratory bacterial pathogens from
patients with community-acquired RTIs to current
and new antibacterials, including the new ketolide
telithromycin.
The study, which now includes 120 centers in over
30 countries, is routinely collecting demographic
information, including patient age, gender, and
in- and out-patient status, as well as isolate
source and infection type. Particular attention is
placed on the isolation of the three most important
community-acquired RTI pathogens, namely Strep-
tococcus pneumoniae, Haemophilus influenzae and
Moraxella catarrhalis, along with Streptococcus
pyogenes and Staphylococcus aureus. The antibac-terial susceptibilities of these isolates according to
geographic region have been presented in detail
elsewhere.14—16
This paper reports the analysis of the impact of
demographic variables on the antibacterial suscept-
ibility, in particular to telithromycin, of S. pneumo-
niae isolates collected in the first year (1999—2000)
of the PROTEKT study.Methods
Organism collection, storage, and
shipment
During the 1999—2000 respiratory season, 69 cen-
ters in 25 countries contributed isolates to the
PROTEKT global study. These comprised 15 centers
in North America, 13 in Latin America, 29 in Europe,
nine in the Far East, and three in Australasia. Each
center was requested to collect 60 isolates of S.
pneumoniae from clinical samples obtained from
patients with one of the following types of commu-
nity-acquired RTIs: acute/chronic sinusitis, acute/
chronic otitis media, pharyngitis, community-
acquired pneumonia (CAP), acute bacterial exacer-
bations of chronic bronchitis, or acute exacerbation
of chronic obstructive airways disease.
The following culture sources were considered
acceptable: blood, sputum (determined acceptable
if the number of white blood cells exceeded the
number of epithelial cells observed in the Gram
stain), middle-ear fluid, bronchoalveolar lavage,
nasopharyngeal swab or aspirate, and sinus aspi-
rate. Only the first positive isolate from each patient
was included in the study. Exclusion criteria
included isolates from patients with cystic fibrosis,
a nosocomial respiratory tract infection, or those
who had been hospitalized for over 48 hours before
the sample was taken, as well as duplicate strains
and strains originating from existing collections.
Patient demographic data, including patient age,
gender, type of infection, culture source, in- or out-
patient status, specimen accession number, collec-
tion date, but not previous antibiotic treatment,
were requested for each isolate (data collected
from laboratory records). Isolates were shipped to
a central laboratory (GR Micro, London, UK) for
analysis. Procedures for storage and shipment have
been described in detail elsewhere.11
Microbiological and genetic analyses
To minimize the risk of phenotypic variation in
the character of the stored isolate, isolates were
264 D. Hoban et al.subcultured at the central laboratory, and then
re-identified using standard procedures.11 Minimum
inhibitory concentrations (MIC) were determin-
ed using the National Committee for Clinical
Laboratory Standards (NCCLS) broth microdilution
method17 and microplates containing a panel of
lyophilised antibacterials (Sensititre, Trek Diagnos-
tics Ltd. East Grinstead, UK).11 A multiplex rapid
cycle polymerase chain reaction (PCR) method with
microwell-format probe hybridization, as described
previously,18 was used to test for the presence of
erm(A), erm(A) subclass erm(TR), erm(B), erm(C),
and mef(A) genes among macrolide-resistant S.
pneumoniae.
Data analysis
MIC results were interpreted according to published
NCCLS breakpoints (2002),19 where available. The
recently approved NCCLS breakpoints (Fourteenth
Informational Supplement M100-14, in press) of
1 mg/L susceptible, 2 mg/L intermediate and
4 mg/L resistant were used for telithromycin.
Effects of country, culture source and patient
characteristics (age, gender and in- or out-patient
status) upon susceptibility data were analyzed using
univariate comparison and multivariate linear
regression. Patient age was divided into four cate-
gory variables for analysis purposes: infants (chil-
dren aged 2 years), children (aged 3—14 years),
adults (aged 15—64 years) and elderly adults (aged
65 years). Infection type was not included in the
analyses owing to the relatively low compliance to
data collection (54.6% of patients). Univariate ana-
lyses were performed on penicillin, erythromycin,
levofloxacin and telithromycin susceptibility re-
sults. Multivariate linear regression, to determine
the odds of resistance to the given agent, was only
performed on penicillin and erythromycin owing to
the low levels of telithromycin and levofloxacin
resistance. Categorical variables were used for
country, patient age, culture source, gender, and
treatment setting. Logistic regression (SAS v.8.02
[SAS Institute]) was used for multivariate analysis,
Odds ratios (OR) and 95% confidence intervals (95%
CIs) were calculated for those categories that
showed a significant difference (P < 0.05) from
the category baseline. The baseline categories were
as follows: country, United Kingdom (UK); patient
age, adults (15—64 years); culture source, blood;
patient gender, male; treatment setting, in-patient.
The Hosmer-Lemeshow test of goodness of fit of
the model was included. Individual pairwise com-
parisons were performed using either a Chi-square
test or Fisher’s exact test as appropriate.Results
Origin of isolates
During the first year of PROTEKT, 3362 S. pneumo-
niae isolates from patients with community-
acquired RTIs were tested. Information on patient
age, culture source, patient gender, and treatment
setting were available for 85.4%, 86.3%, 86.4%, and
85.6% of isolates, respectively. Of those isolates for
which details of patient age were available, 15.3%
were from infants, 12.6% from children, 42.2% from
adults, and 29.8% from elderly adults. In adults and
elderly adults, the primary culture source for S.
pneumoniae was sputum (673/1198 [56.2%] and
635/846 [75.1%], respectively, among the isolates
for which demographic data were available). In
children, S. pneumoniae was isolated predomi-
nantly from sputum (79/354 [22.3%]) and the naso-
pharynx (73/354 [20.6%]), while in infants the ear
(97/425 [22.8%]), nasopharynx (95/425 [22.4%]),
and sputum (78/425 [18.4%]) were the predominant
culture sources among the isolates for which demo-
graphic data were available.
Univariate analyses of the impact of
demographic variables on in vitro activity
and resistance rates
The antibacterial susceptibilities of isolates
according to geographic region have been pre-
sented in detail elsewhere.14—16 The in vitro activ-
ities of penicillin, erythromycin, levofloxacin and
telithromycin are shown as cumulative MIC distri-
butions for a selection of culture sources in
Figure 1a—d, and according to the patient age
groups in Figure 2a—d. Telithromycin was the most
potent of the antibacterials tested against S. pneu-
moniae, irrespective of patient age or culture
source, with the cumulative MIC distribution curve
for telithromycin being markedly shifted to the
left compared with the other agents. These cumu-
lative MIC distributions indicate that there is a
slight difference in the in vitro activity of teli-
thromycin against isolates from the various culture
sources and the various age groups, but this occurs
only at low concentrations (0.06 mg/L for patient
age and 0.25 mg/L for culture source) after
which points the curves converge and there
appears to be no difference in telithromycin activ-
ity. In contrast, both penicillin and erythromycin
show large separation in cumulative MIC distribu-
tion curves for the various culture sources and the
various patient age groups across the whole con-
centration scale tested.
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Figure 1 Cumulative MIC distribution curves of selected antibacterials against blood, ear, nasopharyngeal, and sputum
isolates of Streptococcus pneumoniae (dotted lines represent NCCLS breakpoints). S, susceptible; I, intermediate; R,
resistant (proposed NCCLS breakpoints for telithromycin).MIC summary data and resistance rates for peni-
cillin, erythromycin, levofloxacin, and telithromy-
cin are summarized according to culture source
(Table 1) and patient characteristics (Table 2).
MIC summary data indicate that demographic vari-
ables appear to have little impact on in vitro activity
of any of the above agents. In contrast, comparison
of resistance rates suggests striking differences
attributable to demographic variables. Penicillin
resistance rates appeared highest among isolates
from the ear (30.5%) and middle-ear fluid (26.7%;
Table 1), while themiddle-ear fluid and nasopharynx
appeared to be major reservoirs of erythromycin
(macrolide) resistance (43.3% and 40.6%, respec-
tively). Pneumococcal isolates from sinus aspirates
had the lowest rates of penicillin resistance (17.5%)
of all the culture sources collected, yet high rates of
erythromycin resistance (35.0%). Blood isolates
were found to have low rates of resistance to both
penicillin (18.7%) and erythromycin (21.3%). Fluor-
oquinolone-resistant S. pneumoniae were isolated
from the sinus (2.2%), throat (1.9%), sputum (1.7%),
bronchoalveolar lavage samples (0.8%), and blood
(0.4%). Only two isolates, one from bronchoalveolarlavage and one from ear fluid, required telithromy-
cin at 4 mg/L for inhibition.
Among S. pneumoniae isolates obtained from
infants, 28.4% were penicillin-resistant, compared
with 20.4% for isolates obtained from older children,
19.0% for isolates from adults, and 25.4% from
elderly adults (Table 2). A similar resistance pattern
was observed for erythromycin: 39.1% of pneumo-
coccal isolates from infants were resistant to this
agent, compared with 32.0%, 28.5% and 36.4% for
isolates from older children, adults, and elderly
adults, respectively. Most of the fluoroquinolone-
resistant S. pneumoniae were recovered from
elderly adults. There were no notable differences
in antibacterial resistance patterns associated with
the gender of the patients or with regard to in- or
out-patient status.
For each culture source, there were marked
differences in the prevalence of S. pneumoniae
resistance to penicillin and to erythromycin among
the age groups (Table 3). Among infants and adults,
pneumococcal isolates from the ear, middle ear and
sputum tended to have the highest prevalence of
resistance to penicillin (infants: 39.2%, 37.5% and
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Figure 2 Cumulative MIC distribution curves of selected antibacterials against isolates of Streptococcus pneumoniae
according to patient age group, infant 0—2 years, child 3—14 years, adult 15—64 years, elderly 65 years (dotted lines
represent NCCLS breakpoints). S, susceptible; I, intermediate; R, resistant (proposed NCCLS breakpoints for telithro-
mycin).29.5%; adults: 24.3%, 22.2% and 21.7%, respec-
tively), while in the elderly population, bronchoal-
veolar lavage, sputum, and nasopharynx were the
primary sources of penicillin-resistant S. pneumo-
niae (30.5%, 27.7% and 26.7%, respectively). Chil-
dren had the highest prevalence of penicillin
resistance among isolates from throat, nasopharynx
and blood (26.9%, 24.7% and 24.4%, respectively).
Rates of macrolide resistance exceeded 40% in S.
pneumoniae cultured from middle-ear fluid, the
nasopharynx, and the sinuses of infants; the naso-
pharynx and sinuses of older children; and isolates
from bronchoalveolar lavage samples and sputum of
elderly adults.
Multivariate analyses of the impact of
demographic variables on resistance rates
Multivariate logistic regression models were fitted
to determine which countries and demographic fac-
tors were primarily associated with the frequency of
pneumococcal resistance to penicillin and erythro-mycin. There were too few telithromycin-resistant
and levofloxacin-resistant S. pneumoniae isolates to
show any statistical difference in resistance rates
between the country and demographic variables.
Country, culture source and patient age were found
to be significant predictors of resistance to penicil-
lin, while country, patient age and gender were
significant predictors of resistance to erythromycin
(Table 4). Data on previous antibacterial therapy
were not available for analyses.
The odds of penicillin resistance were 5.92-fold
(Mexico) to 49.95-fold (South Korea) significantly
higher in eight PROTEKT countries than in the UK
(Table 4). Similarly, the odds of erythromycin resis-
tance were 2.50-fold (Mexico) to 64.79-fold (South
Korea) significantly higher in 11 PROTEKT countries
than in the UK.
After adjustment for country and other demo-
graphic factors, ear swabs were the only culture
source associated with significantly higher odds (OR
2.07) of penicillin resistance than blood isolates.
None of the culture sources were associated with
Demographic analysis of antimicrobial resistance among Streptococcus pneumoniae 267
Ta
b
le
1
In
vi
tr
o
ac
ti
vi
ty
o
f
se
le
ct
e
d
an
ti
b
ac
te
ri
al
s
ag
ai
n
st
St
re
p
to
co
cc
u
s
p
n
e
u
m
o
n
ia
e
(n
=
33
62
):
an
al
ys
is
b
y
cu
lt
u
re
so
u
rc
e
.
C
u
lt
u
re
so
u
rc
e
N
o
.
o
f
is
o
la
te
s
Te
li
th
ro
m
yc
in
Pe
n
ic
il
li
n
E
ry
th
ro
m
yc
in
Le
vo
fl
o
xa
ci
n
M
IC
(m
g/
L)
%
R
1
M
IC
(m
g/
L)
%
R
2
M
IC
(m
g/
L)
%
R
2
M
IC
(m
g/
L)
%
R
2
M
IC
5
0
M
IC
9
0
R
an
ge
M
IC
5
0
M
IC
9
0
R
an
ge
M
IC
5
0
M
IC
9
0
R
an
ge
M
IC
5
0
M
IC
9
0
R
an
ge
B
lo
o
d
50
2
0.
00
8
0.
12
0
.0
02
—
1
0
0.
01
5
2
0
.0
08
—
>
4
18
.7
0.
06
>
64
0
.0
3
—
>
64
21
.3
1
1
0
.5
—
8
0.
4
B
A
L
25
8
0.
01
5
0.
25
0.
00
4
—
4
0.
4
0.
03
2
0
.0
08
—
4
21
.3
0.
06
>
6
4
0
.0
3
—
>
64
31
.4
1
1
0
.5
—
16
0.
8
E
ar
20
3
0.
01
5
0.
25
0
.0
02
—
8
0.
5
0.
06
4
0
.0
08
—
>
4
30
.5
0.
06
>
64
0
.0
3
—
>
64
36
.9
1
1
0
.5
—
4
0
M
id
d
le
-e
ar
fl
u
id
30
0.
00
8
0.
12
0.
00
4
—
1
0
0.
01
5
2
0.
01
5
—
>
4
26
.7
0.
06
>
6
4
0
.0
3
—
>
64
43
.3
1
1
0
.5
—
1
0
N
as
o
p
h
ar
yn
x
23
4
0.
01
5
0.
12
0.
00
8
—
0.
5
0
0.
03
4
0
.0
08
—
4
24
.4
0.
06
>
6
4
0
.0
3
—
>
64
40
.6
1
1
0
.5
—
2
0
Si
n
u
s
13
7
0.
01
5
0.
12
0.
00
8
—
1
0
0.
03
2
0
.0
08
—
>
4
17
.5
0.
06
>
6
4
0
.0
3
—
>
64
35
.0
1
1
0
.5
—
32
2.
2
Sp
u
tu
m
14
82
0.
01
5
0.
12
0.
00
4
—
1
0
0.
03
2
0
.0
08
—
>
4
24
.6
0.
06
>
6
4
0
.0
3
—
>
64
35
.5
1
1
0
.5
—
32
1.
7
T
h
ro
at
54
0.
00
8
0.
06
0.
00
8
—
0.
25
0
0.
03
2
0
.0
08
—
4
20
.4
0.
06
>
6
4
0
.0
3
—
>
64
16
.7
1
1
0
.5
—
8
1.
9
U
n
sp
e
ci
fi
e
d
46
2
0.
01
5
0.
06
0.
00
4
—
0.
5
0
0.
03
2
0
.0
08
—
>
4
14
.9
0.
06
>
6
4
0
.0
3
—
>
64
19
.8
1
1
0
.5
—
16
0.
4
B
A
L
=
b
ro
n
ch
o
al
ve
o
la
r
la
va
ge
;
R
1
=
re
si
st
an
t
ac
co
rd
in
g
to
p
ro
p
o
se
d
N
C
C
LS
b
re
ak
p
o
in
t
(t
e
li
th
ro
m
yc
in
-r
e
si
st
an
t,
M
IC
4
m
g/
L)
;
R
2
=
re
si
st
an
t
ac
co
rd
in
g
to
N
C
C
LS
b
re
ak
p
o
in
ts
(p
e
n
ic
il
li
n
-
re
si
st
an
t,
M
IC
2
m
g/
L;
e
ry
th
ro
m
yc
in
-r
e
si
st
an
t,
M
IC
1
m
g/
L;
le
vo
fl
o
xa
ci
n
-r
e
si
st
an
t,
M
IC
8
m
g/
L)
.effects upon the prevalence of erythromycin resis-
tance.
After adjustment for other factors, pneumococ-
cal isolates from infants had significantly higher
odds of both penicillin resistance (1.98) and ery-
thromycin resistance (1.89) than isolates from
adults (Table 4); isolates from children and elderly
adults were not significantly different to those from
adults. Isolates from males had 0.69 times lower
adjusted odds of erythromycin resistance than did
isolates from females. Treatment setting was not
associated with significant differences in the pre-
valences of penicillin or erythromycin resistance.
Impact of demographic variables on
macrolide resistance mechanisms
Table 5 shows the distribution of macrolide resis-
tance mechanisms among erythromycin-resistant S.
pneumoniae, according to univariate analyses of
demographic and clinical parameters. Erm(B) was
the predominant mechanism of resistance across all
age groups and, among sources with >10 erythro-
mycin-resistant isolates, was particularly prevalent
from bronchoalveolar lavage (69.1%) and sinus
(68.8%) samples. Over 10% of S. pneumoniae iso-
lated from infants or children were found to test
positive for both erm(B) and mef(A) mechanisms;
the majority of these isolates being collected in
South Korea. Among the isolates from the ear or
middle ear, the population carrying both erm(B) and
mef(A) (17.3% or 15.4%, respectively) was high
relative to the populations carrying either the
erm(B) (42.7% or 53.8%, respectively) or mef(A)
(37.3% or 30.8%, respectively) resistance mechan-
ism alone. No differences in the distribution of
macrolide resistance mechanisms were associated
with gender or inpatient/outpatient setting.
Multivariate analyses were not undertaken due to
the complexity of the model required to accommo-
date at least four genotype groups.Discussion
In response to the worldwide problem of antibacter-
ial resistance, strategic programmes for controlling
theemergenceand spreadof antibacterial resistance
are being implemented at international, national,
and regional levels.20—22 Resistance surveillance stu-
dies are an integral component of many of these
strategies.9,23 For surveillance studies to be of clin-
ical value to the physician making choices about
empirical antibacterial therapy, ideally they should
collect isolates from specific infection sites in care-
fully defined patient populations.9 Collection of
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Table 2 In vitro activity of selected antibacterials against Streptococcus pneumoniae (n = 3362): analysis by patient age group, gender, and treatment setting.
No. of isolates Telithromycin Penicillin Erythromycin Levofloxacin
MIC (mg/L) %R1 MIC (mg/L) %R2 MIC (mg/L) %R2 MIC (mg/L) %R2
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Age group (years)
0—2 440 0.015 0.25 0.002—1 0 0.06 4 0.008—>4 28.4 0.06 >64 0.03—>64 39.1 1 1 0.5—2 0.0
3—14 362 0.015 0.12 0.002—0.5 0 0.03 2 0.008—4 20.4 0.06 >64 0.03—>64 32.0 1 1 0.5—8 0.3
15—64 1213 0.015 0.12 0.004—8 0.1 0.015 2 0.008—>4 19.0 0.06 >64 0.03—>64 28.5 1 1 0.5—32 1.0
65 857 0.015 0.12 0.004—4 0.1 0.03 2 0.008—>4 25.4 0.06 >64 0.03—>64 36.4 1 1 0.5—32 2.3
Unspecified 490 0.015 0.06 0.004—0.5 0 0.03 2 0.008—>4 19.6 0.006 >64 0.03—>64 19.8 1 1 0.5—16 0.4
Gender
Male 1831 0.015 0.12 0.004—8 0.1 0.03 2 0.008—>4 24.2 0.06 >64 0.03—>64 32.0 1 1 0.5—32 1.2
Female 1073 0.015 0.25 0.002—1 0 0.015 2 0.008—>4 21.0 0.06 >64 0.03—>64 32.8 1 1 0.5—16 0.9
Unspecified 458 0.015 0.12 0.004—0.5 0 0.03 2 0.008—>4 16.6 0.06 >64 0.03—>64 22.9 1 1 0.5—16 0.7
Treatment setting
Inpatient 1452 0.015 0.12 0.004—4 0.1 0.015 2 0.008—>4 23.1 0.06 >64 0.03—>64 31.7 1 1 0.5—32 1.0
Outpatient 1425 0.015 0.12 0.002—8 0.1 0.03 2 0.008—>4 23.9 0.06 >64 0.03—>64 35.1 1 1 0.5—32 1.2
Unspecified 483 0.015 0.06 0.004—0.5 0 0.03 2 0.008—>4 13.9 0.06 16 0.03—>64 17.0 1 1 0.5—16 0.6
R1 = resistant according to proposed NCCLS breakpoint (telithromycin-resistant, MIC 4 mg/L); R2 = resistant according to NCCLS breakpoints (penicillin-resistant, MIC 2 mg/L;
erythromycin-resistant, MIC 1 mg/L; levofloxacin-resistant, MIC 8 mg/L).
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L.demographic and source data (such as patient age,
culture source, infection type, community- or hos-
pital-acquired infection), which are often missing
from surveillance reports, and the ability to analyze
the data according to these parameters are impor-
tant to reduce bias anderror arising fromvariation in
the sample population, and to answer the question
of relevance to the physician.8 Moreover, given the
unpredictability of resistance development, the
more information available on the potential popula-
tion sources of significant new resistance develop-
ments, the more likely are the chances to introduce
appropriate interventions in a timely fashion to limit
the spreadof the resistant pathogens and reduceany
potential adverse health impact.
A number of international surveillance studies
have tracked the susceptibility of RTI pathogens
(e.g., Alexander, SENTRY).1,24 While these studies
provide a wealth of useful information, one of their
major drawbacks has been in the limited collection
of demographic and clinical data.8 This need has
been addressed in the design of the PROTEKTstudy,
which collects information on patient age, gender,
type of infection, culture source, and in- or out-
patient status from patients with community-
acquired RTIs. In the first year report from the study
on S. pneumoniae, compliance with demographic
data on culture source, patient age, patient gender,
and treatment setting was high (>85%). Compliance
with the collection of demographic data and the
integrity of the data collected was encouraged by
the use of electronic spreadsheets with preset
choices for selection, by limiting the amount of data
that investigators needed to collect to fulfill the
study objectives, and by the use of a detailed study
protocol. To the authors’ knowledge this is the most
comprehensive collection of demographic and clin-
ical data as part of a large-scale international resis-
tance surveillance study of respiratory pathogens to
date.
To ensure patient confidentiality, demographic
and clinical information were not collected from
source, but ‘second hand’ from laboratory records.
This has obvious limitations in terms of the type
of data that can be collected, as well as in the
completeness of the data. In this study, completion
of information on disease type was low compared
with the other demographic parameters, and this
parameter was therefore not included as a variable
in the logistic regression analysis. The low compli-
ance with the collection of data on disease type
might reflect in part problems of ‘second-hand’
data collection, as well as concerns regarding iden-
tification of individual patients via collecting cer-
tain types of information. A more complete picture
of the influence of demographic and clinical para-
270 D. Hoban et al.
Table 4 Results of multivariate logistic regression analysis on prevalence of penicillin resistance and erythromycin
resistance among Streptococcus pneumoniae (n = 3362) isolated from patients with community-acquired respiratory
tract infections during 1999—2000.
Penicillin resistancea Erythromycin resistanceb
Odds ratioc (95% CI) P value Odds ratioc (95% CI) P value
Country
UKd 1 (—) — 1 (—) —
Belgium 3.13 (1.06—9.22) 0.0384
Eire 11.09 (3.75—32.78) <0.0001 3.20 (1.33—7.73) 0.0096
France 17.90 (6.80—47.09) <0.0001 10.84 (5.39—21.78) <0.0001
Hong Kong 27.85 (9.88—78.50) <0.0001 22.07 (9.72—50.07) <0.0001
Hungary — NS 9.99 (4.36—22.09) <0.0001
Italy — NS 5.78 (2.80—11.92) <0.0001
Japan 15.50 (6.05—39.77) <0.0001 28.85 (14.52—57.36) <0.0001
Mexico 5.92 (2.15—16.35) 0.0006 2.50 (1.18—3.87) 0.0168
S. Korea 49.95 (18.56—134.50) <0.0001 64.79 (28.62—146.67) <0.0001
Spain 9.82 (3.44—28.05) <0.0001 4.46 (2.00—9.94) 0.0003
USA 10.41 (4.00—27.12) <0.0001 3.41 (1.72—6.75) 0.0004
Culture source
Bloodd 1 (—) — 1 (—) —
Ear 2.07 (1.27—3.38) 0.0037 — NS
Age (years)
0—2d 1.98 (1.42—2.77) <0.0001 1.89 (1.37—2.60) <0.0001
3—14 1.09 (0.74—1.61) NS 0.98 (0.69—1.41) NS
15—64 1 (—) — 1 (—) —
65 1.14 (0.88—1.47) NS 1.01 (0.79—1.28) NS
Gender
Maled 1 (—) — 1 (—) —
Female — NS 0.69 (0.56—0.84) 0.0003
Treatment setting
Inpatientd 1 (—) — 1 (—) —
Outpatient — NS — NS
BAL = bronchoalveolar lavage; CI = confidence intervals.
a Penicillin-resistant, MIC 2 mg/L.
b Erythromycin-resistant, MIC 1 mg/L.
c Odds ratios calculated only for those groups found to be significantly different from the reference group.
d Reference group.meters on resistance patterns could be obtained by
collecting data on these parameters at source. How-
ever, to run resistance surveillance as a true epide-
miological/clinical study would have significant
confidentiality and cost implications and necessi-
tate collection of informed patient consent, making
it impractical for large-scale international surveys,
such as the present study.
Despite the limitations of ‘second-hand’ data
collection, this study has highlighted some striking
and highly significant relationships between resis-
tance prevalence in S. pneumoniae and demo-
graphic parameters using both univariate and
multivariate analyses. Univariate analyses indicated
marked effects of patient age and culture source;
however such analyses do not take into account
local or national prescribing practices, resistance
levels and culture sampling procedures (e.g. tym-panocentesis) which may introduce a bias into the
results. Using a multivariate logistic regression
model, it was found that country, culture source
(ear swabs) and patient age were significant pre-
dictors of resistance to penicillin, while country,
patient age and gender were significant predictors
of resistance to erythromycin. The prevalence of
penicillin and/or erythromycin resistance was sig-
nificantly higher in 18 of the participating countries
other than in Germany. The multivariate logistic
regression model also enables quantifying the mag-
nitude of the effect of each variable using an odds
ratio. The odds ratios associated with these coun-
tries were higher than any of the odds ratios deter-
mined for culture source, patient age and patient
gender. Among culture sources, only ear swabs, with
an odds ratio of 2.07, were significantly more likely
to exhibit penicillin resistance than blood cultures.
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Table 5 Distribution of macrolide resistance mechanisms among erythromycin-resistant Streptococcus pneumoniae
according to demographic parameters.
ERY-R Genotype
n erm(B) erm(A) subclass
erm(TR)
mef(A) mef(A) & erm(B) Negative
n (%) n (%) n (%) n (%) n (%)
Culture source
Blood 107 55 (51.4) 0 (0.0) 44 (41.1) 5 (4.7) 3 (2.8)
BAL 81 56 (69.1) 0 (0.0) 21 (25.9) 3 (3.7) 1 (1.2)
Ear 75 32 (42.7) 1 (1.3) 28 (37.3) 13 (17.3) 1 (1.3)
Middle-ear fluid 13 7 (53.8) 0 (0.0) 4 (30.8) 2 (15.4) 0 (0.0)
Nasopharynx 95 49 (51.6) 0 (0.0) 37 (38.9) 8 (8.4) 1 (1.1)
Sinus 48 33 (68.8) 0 (0.0) 13 (27.1) 2 (4.2) 0 (0.0)
Sputum 526 304 (57.8) 0 (0.0) 178 (33.8) 33 (6.3) 11 (2.1)
Throat 9 6 (66.7) 0 (0.0) 2 (22.2) 1 (11.1) 0 (0.0)
Age (years)
0—2 172 82 (47.7) 0 (0.0) 71 (41.3) 18 (10.5) 1 (0.6)
3—14 116 63 (54.3) 1 (0.9) 39 (33.6) 12 (10.3) 1 (0.9)
15—64 346 202 (58.4) 0 (0.0) 111 (32.1) 22 (6.3) 11 (3.2)
65 312 183 (58.7) 0 (0.0) 107 (34.3) 17 (5.4) 5 (1.6)
Gender
Male 586 345 (58.9) 0 (0.0) 170 (29.0) 44 (7.5) 7 (1.2)
Female 352 184 (52.3) 1 (0.3) 135 (38.4) 25 (7.1) 7 (2.0)
Treatment setting
Inpatient 461 276 (59.9) 0 (0.0) 149 (32.3) 28 (6.1) 8 (1.7)
Outpatient 500 268 (53.6) 1 (0.2) 180 (36.0) 41 (8.2) 10 (2.0)
BAL = bronchoalveolar lavage; ERY-R = erythromycin-resistant (MIC 1 mg/L).It was also found that the adjusted odds of penicillin
resistance and erythromycin resistance among iso-
lates from infants to be significantly higher (1.98
and 1.89, respectively) than among isolates from
adults. These findings are consistent with those from
other studies reported in the literature.10,12,25—27
Among children aged 6 years, Arason and collea-
gues found by multivariate analysis that age <2
years significantly increased the odds of carrying
penicillin-resistant pneumococci (by 3.5—4-fold
compared with children aged 2—6 years).25 Simi-
larly, Weiss et al. have recently shown in a surveil-
lance study of pneumococci circulating in Quebec
during the 2000—2001 winter season that resistance
to macrolides and to penicillin was higher among
invasive than non-invasive isolates, and among
pediatric isolates compared with those obtained
from adults.27 In their study, Weiss et al. failed to
find any significant relationship between pneumo-
coccal resistance and patient gender.27 In the pre-
sent study, however, a lower odds ratio (0.69) of
pneumococcal erythromycin resistance in males
than in females was found.
Erm(B) was the predominant mechanism of
macrolide resistance among S. pneumoniae across
all age groups and culture sources, and was parti-
cularly prevalent among S. pneumoniae isolatesobtained from bronchoalveolar lavage and sinus
samples. The product of this gene modifies the
ribosomal target site of the macrolides by dimethy-
lating a specific adenine residue on the 23S rRNA
(A2058 — Escherichia coli numbering). The resulting
conformational change in the ribosome produces
decreased binding of all macrolide, lincosamide
and streptogramin B antibacterials (the so-called
MLSB phenotype), and high-level resistance to these
agents.28—30 Erm(A) subclass erm(TR) has also
recently been reported in S. pneumoniae,31 and
was found in one macrolide-resistant pneumococcal
isolate in the present study, from an ear sample
obtained from a three-year-old girl in Australia.
Overall, 35.0% (365/1043) of macrolide-resistant
S. pneumoniae in the present study tested positive
for the product of the mef(A) gene, indicating that
macrolide resistance in these isolates was due to
drug efflux,29 and 6.8% (71/1043) tested positive for
both erm(B) and mef(A). This dual resistance
mechanism, which generally causes high-level MLSB
resistance, was particularly prevalent among chil-
dren and among isolates from the ear/middle-ear
fluid [20.8% (10/48) of macrolide-resistant S. pneu-
moniae isolated from ear/middle-ear fluid samples
from children 2 years tested positive for this dual
mechanism of resistance in the present study].
272 D. Hoban et al.Further investigation of 16 of the isolates that
tested negative for the mechanisms studied, found
all were susceptible to telithromycin and that
macrolide resistance was conferred by ribosomal
gene mutations.32
The fluoroquinolones showed different patterns
of pneumococcal resistance to the other agents,
reflecting differences in their licensed indications
including the absence of pediatric usage. Levoflox-
acin resistance was extremely rare among S. pneu-
moniae isolated from children, as anticipated, and
no levofloxacin-resistant pneumococci were iso-
lated from the ear/middle-ear fluid or from the
nasopharynx. The highest rates of levofloxacin-
resistant pneumococci were reported in elderly
adults (2.3%) and in isolates obtained from the sinus
(2.2%), throat (1.9%) and from sputum (1.7%),
although the small numbers of levofloxacin-resis-
tant isolates collected precluded statistical analy-
sis.
Antibiotic consumption and its impact upon anti-
microbial resistance is not included in the PROTEKT
study. However, studies conducted elsewhere have
shown a strong correlation between high antibiotic
consumption and the highest rates of selection of
resistant organisms at patient, community, region or
country level, prompting recommendations for
greater controls on antibiotic usage.34—36
One of the objectives of the PROTEKT study was
to provide current surveillance data for the ketolide
telithromycin at its time of launch into clinical
practice and to track its susceptibility with time.
Previously reported data from PROTEKT have shown
that this ketolide has good in vitro activity against
bacterial pathogens implicated in community-
acquired RTIs, including S. pneumoniae isolates that
are resistant to penicillin, macrolides, and/or fluor-
oquinolones.33 Only two (0.06%) isolates were resis-
tant to telithromycin (MIC 4 and 8 mg/L). Both
were multi-resistant isolates, carrying the erm(B)
mechanism of macrolide resistance, and associated
with different demographic variables (one isolate
from bronchoalveolar lavage fluid, elderly male,
France; the other from ear culture, adult male,
Italy). Overall, this present analysis found that
the high in vitro activity of telithromycin was largely
unrelated to any of the demographic variables col-
lected.
In summary, this analysis of the PROTEKT 1999—
2000 database has shown some striking and highly
significant differences in resistance prevalence
among the key respiratory bacterial pathogens when
analyzed according to country, demographic and
clinical parameters, and highlights the importance
of collecting patient data routinely as part of anti-
bacterial surveillance.Acknowledgements
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